glp-1 drug boom The Weight-Loss (GLP-1): Why Nutrition Matters More Than Ever El boom de los medicamentos para adelgazar (GLP-1): por qué la nutrición importa ahora más que nunca Chart: 1 in 8 Americans

Endocrine disruptors and obesity

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3

Sleep Apnea and Inflammation - Getting a Good Night's Sleep with Omega-3 Supplementation

Nat Rev Immunol (2007) 7:80315

Notable safety advantages : Lower discontinuation rates due to adverse events (4-7%) compared to reported rates with semaglutide 2.4 mg in STEP trials (approximately 6-7%) No signal for diabetic retinopathy worsening (a concern identified with semaglutide in SUSTAIN-6) No evidence of increased psychiatric adverse events (depression, suicidality) Research Applications Tirzepatide serves as a groundbreaking research tool across multiple biomedical domains: Dual incretin biology : Studying the synergistic effects of simultaneous GIP and GLP-1 receptor activation on glucose homeostasis, appetite, and metabolism Adipose tissue biology : Investigating GIPR-mediated effects on adipocyte differentiation, lipid buffering, and adipokine secretion mechanisms absent from GLP-1 agonist research Central appetite neuroscience : Mapping distinct GIP vs